During the last session, Twist Bioscience Corp (NASDAQ:TWST)’s traded shares were 0.56 million, with the beta value of the company hitting 2.35. At the end of the trading day, the stock’s price was $40.36, reflecting an intraday loss of -2.93% or -$1.22. The 52-week high for the TWST share is $60.90, that puts it down -50.89 from that peak though still a striking 32.09% gain since the share price plummeted to a 52-week low of $27.41. The company’s market capitalization is $2.41B, and the average intraday trading volume over the past 10 days was 0.82 million shares, and the average trade volume was 960.84K shares over the past three months.
Twist Bioscience Corp (TWST) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.77. TWST has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.57.
Twist Bioscience Corp (NASDAQ:TWST) trade information
Twist Bioscience Corp (TWST) registered a -2.93% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.93% in intraday trading to $40.36, hitting a weekly high. The stock’s 5-day price performance is -5.90%, and it has moved by 4.67% in 30 days. Based on these gigs, the overall price performance for the year is 19.59%. The short interest in Twist Bioscience Corp (NASDAQ:TWST) is 8.83 million shares and it means that shorts have 7.21 day(s) to cover.
The consensus price target of analysts on Wall Street is $56, which implies an increase of 27.93% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $54 and $58 respectively. As a result, TWST is trading at a discount of -43.71% off the target high and -33.8% off the low.
Twist Bioscience Corp (TWST) estimates and forecasts
In the rating firms’ projections, revenue will increase 20.15% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 92M as predicted by 10 analyst(s). Meanwhile, a consensus of 10 analyst(s) estimates revenue growth to 95.71M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 75.3M and 81.46M respectively. In this case, analysts expect current quarter sales to grow by 22.18% and then jump by 17.48% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 1.70%. While earnings are projected to return 43.45% in 2025, the next five years will return 37.54% per annum.
TWST Dividends
Twist Bioscience Corp is due to release its next quarterly earnings on 2025-Feb-02. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Twist Bioscience Corp (NASDAQ:TWST)’s Major holders
Twist Bioscience Corp insiders own 2.16% of total outstanding shares while institutional holders control 112.28%, with the float percentage being 114.76%. ARK INVESTMENT MANAGEMENT LLC is the largest shareholder of the company, while 360.0 institutions own stock in it. As of 2024-06-30, the company held over 6.13 million shares (or 10.5415% of all shares), a total value of $302.06 million in shares.
The next largest institutional holding, with 6.07 million shares, is of ARTISAN PARTNERS LIMITED PARTNERSHIP’s that is approximately 10.4371% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $299.06 million.
Also, the Mutual Funds coming in first place with the largest holdings of Twist Bioscience Corp (TWST) shares are ARK ETF Trust-ARK Innovation ETF and ARK ETF Trust-ARK Genomic Revolution ETF . Data provided on Feb 28, 2025 indicates that ARK ETF Trust-ARK Innovation ETF owns about 3.59 shares. This amounts to just over 6.02 percent of the company’s overall shares, with a $144.86 million market value. The same data shows that the other fund manager holds slightly less at 2.34, or about 3.92% of the stock, which is worth about $94.41 million.
